
PASSAGE BIO (PASG) Stock Forecast & Price Target
PASSAGE BIO (PASG) Analyst Ratings
Bulls say
Passage Bio Inc. has demonstrated promising results in its June 2025 interim upliFT-D study, showing a significant increase in the mean cerebrospinal fluid (CSF) PGRN levels from less than 2 ng/mL at baseline to a peak concentration of 25.9 ng/mL, which reflects the durability of Dose 1 therapy over 18 months. The observed plasma neurofilament light chain (NfL) increase of 4% further supports the company’s efforts in addressing critical pathology in neurodegenerative diseases. These encouraging clinical findings position Passage Bio favorably in the genetic medicines sector, particularly for the treatment of rare, monogenic CNS disorders, despite potential competition in the gene therapy landscape.
Bears say
Passage Bio's stock outlook is negatively affected by the potential for delays in clinical development for its pipeline products, PBGM01 and PBFT02, due to unforeseen safety issues and efficacy levels that may fall short of expectations. Additionally, there are significant regulatory risks that could impede progress and market entry, alongside challenges in defending its patents, which could lead to increased competition in the rapidly evolving gene therapy landscape. The uncertainty surrounding long-term treatment durability, particularly in light of previous clinical outcomes such as those observed with LLY's AAV9-based PR007, adds further concerns regarding the company's future performance in this sector.
This aggregate rating is based on analysts' research of PASSAGE BIO and is not a guaranteed prediction by Public.com or investment advice.
PASSAGE BIO (PASG) Analyst Forecast & Price Prediction
Start investing in PASSAGE BIO (PASG)
Order type
Buy in
Order amount
Est. shares
0 shares